- Home
- APVO vs DWTX Comparison
APVO vs DWTX Comparison
Compare APVO & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- DWTX
- Stock Information
- Founded
- APVO 2016
- DWTX 2012
- Country
- APVO United States
- DWTX United States
- Employees
- APVO N/A
- DWTX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- DWTX
- Sector
- APVO Health Care
- DWTX
- Exchange
- APVO Nasdaq
- DWTX NYSE
- Market Cap
- APVO 3.7M
- DWTX 4.0M
- IPO Year
- APVO N/A
- DWTX N/A
- Fundamental
- Price
- APVO $0.21
- DWTX $3.04
- Analyst Decision
- APVO Strong Buy
- DWTX
- Analyst Count
- APVO 1
- DWTX 0
- Target Price
- APVO $8.00
- DWTX N/A
- AVG Volume (30 Days)
- APVO 17.5M
- DWTX 49.4K
- Earning Date
- APVO 11-07-2024
- DWTX 11-07-2024
- Dividend Yield
- APVO N/A
- DWTX N/A
- EPS Growth
- APVO N/A
- DWTX N/A
- EPS
- APVO N/A
- DWTX N/A
- Revenue
- APVO N/A
- DWTX N/A
- Revenue This Year
- APVO N/A
- DWTX N/A
- Revenue Next Year
- APVO N/A
- DWTX N/A
- P/E Ratio
- APVO N/A
- DWTX N/A
- Revenue Growth
- APVO N/A
- DWTX N/A
- 52 Week Low
- APVO $0.14
- DWTX $2.50
- 52 Week High
- APVO $10.80
- DWTX $23.50
- Technical
- Relative Strength Index (RSI)
- APVO 43.68
- DWTX N/A
- Support Level
- APVO $0.24
- DWTX N/A
- Resistance Level
- APVO $0.33
- DWTX N/A
- Average True Range (ATR)
- APVO 0.04
- DWTX 0.00
- MACD
- APVO -0.01
- DWTX 0.00
- Stochastic Oscillator
- APVO 0.70
- DWTX 0.00
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.